InVivo Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries, today announced the pricing of an underwritten public offering of 8,281,574 shares of its common stock, offered at a price to the public of $2.10 per share, for gross proceeds of approximately $17.4 million. Net proceeds to InVivo, after deducting underwriting discounts and commissions and other offering expenses, are expected

Feed Date: 
Fri, 2012-02-17 01:05